Reactions Weekly newsletter publishes 1,500th issue

Adis, the leading publisher of drug safety and pharmacovigilance content, has been publishing expert summaries of drug safety news for over 30 years.

Another Adis title reached a significant milestone this week when it published its 1,500th issue on SpringerLink.

Reactions Weekly is an online publication focusing on adverse drug reactions and drug safety news. The newsletter, which includes news from The Uppsala Monitoring Centre, has been publishing summaries of the world’s adverse drug reaction news and case reports for more than 30 years.

The weekly newsletter provides a round-up of news including labelling changes, drug withdrawals due to safety issues, adverse reaction research and current issues in drug safety. Content is sourced from journals, scientific meetings, media releases, regulatory agency websites, and bulletins from the National Centers that participate in the WHO International Drug Monitoring Programme. Each report is read and summarized by a member of the expert editorial team.

Editor, Suzanne Berresford, states:

“I think I speak on behalf of the whole Reactions team when I say that I am very proud to work on a publication that has truly stood the test of time. Reactions Weekly has been through a lot of changes since its launch in the 1980s, shifting from print publication to purely online, for example, in response to our changing customer needs. One thing is clear though – the service we provide in summarizing news and case reports so that they are quick and easy-to-read is even more valuable today as our readers are under increasing time pressure in their roles”.

Reactions Weekly is part of a suite of pharmacovigilance and drug safety solutions from Adis that also includes the Drug Safety journal, Pharmacovigilance Insight database and the Reactions Pharmacovigilance Service.

Browse the latest issue of Reactions Weekly online or read more on

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.